Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Norgestrel→

Norgestrel Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
6533-00-2
Molecular formula
C21H28O2
Molecular weight
312.4 g/mol
Drug class
Synthetic progestogensteroidal progestin used in hormonal contraception
Mechanism of action
Activates progesterone receptors and, in combined oral contraceptives, suppresses ovulation. Additional contraceptive actions include thickening cervical mucus and producing endometrial changes that reduce the likelihood of pregnancy.
Indications / reported uses
  • Contraception in combination with ethinyl estradiol in authorised combined oral contraceptive products.

Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/018206s022lbl.pdf · https://pubchem.ncbi.nlm.nih.gov/compound/Norgestrel · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Norgestrel Environmental Risk Assessment (ERA) (the Norgestrel ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.